TCG Lifesciences and Endo enter discovery alliance
This article was originally published in Scrip
Executive Summary
TCG Lifesciences, a research services and informatics company, is collaborating with Endo Pharmaceuticals to discover novel small-molecule drug candidates for the treatment of pain. The tie-up will focus on an integrated approach involving medicinal chemistry, biology and animal pharmacology capabilities of TCG's discovery research arm, Chembiotek. Endo will have full ownership of the compounds developed under the collaboration as well as exclusive global rights. It will also finance all subsequent drug development and commercialisation activities, provide research funding and make milestone payments to TCG. TCG is based in India and is part of The Chatterjee Group, an investment conglomerate headquartered in New York.